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While fundamental concepts outlined in the 
2018 consensus [1] will be revisited, emphasis 
will be placed on the more recent developments.
Definition and epidemiology:  
Constantly increasing burden and  
importance of hyperuricemia
Uric acid (UA) is the end product of purine 
metabolism, and its concentration in blood can 
increase in humans, great apes, and dalmatian 
dogs as a consequence of a genetic mutation that 
occurred millions of years ago and contribute to hu-
man evolution from less evolved species [2]. These 
elevated plasma levels of UA are the final result of 
almost three different mechanisms under genetic 
control and involve UA production, renal excretion, 
and gut absorption [3]. Under physiological condi-
tions, UA synthesis and excretion are balanced in 
the body. Once this balance is disturbed, it leads 
to hyperuricemia (HU). Typically, male UA levels 
greater than 7 mg/dL (420 μmol/L) and female 
UA levels greater than 6 mg/dL (360 μmol/L) are 
considered hyperuricemia.
The latest scientific data published after our 
first consensus [4, 5] indicates that mean serum 
uric acid (sUA) has increased constantly according 
to the prevalence of concomitant diseases in many 
populations, while the prevalence of HU increases 
with age and is higher in men than premenopausal 
women due to estrogen’s positive influence on 
urate excretion by the kidneys [4]. The United 
States National Health and Nutrition Examination 
Survey (NHANES 2007–2016) estimated the HU 
prevalence to be 20.2% for men (22.8 million) and 
20.0% for women (24.4 million). In simple terms, 
1 in 5 men and 1 in 5 women suffer from HU. The 
prevalence of sUA levels > 6.0 mg/dL was 32.3% 
overall (75.8 million), 49.5% among men (55.8 
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The overall mean sUA level was 5.39 mg/dL (95% 
confidence interval [CI] 5.34–5.45), with mean sUA 
levels of 6.04 mg/dL and 4.79 mg/dL among men 
and women, respectively. Moreover, the prevalence 
rates of HU remained stable between 2007 and 
2016 (p for trend > 0.05) [5]. Of note, the preva-
lence of HU increased with age, with the highest 
being 27.8% (3.1 million) among individuals aged 
80 years or older. Among patients aged 65 years 
or older, the prevalence of HU was 27.2% (12.6 
million) [5]. Recently published data by the Irish 
health system indicate that from 2006 to 2014, 
the prevalence of HU increased from 19.7% to 
25.0% in men and from 20.5% to 24.1% in women 
(p < 0.001). Moreover, age-specific prevalence 
increased in all groups from 2006 to 2014, and the 
magnitudes of the increases were similar for each 
age category [6]. 
The prevalence of HU increased significantly 
with worsening renal function, from 12.2% in 
patients with estimated glomerular filtration rate 
(eGFR) > 90 mL/min to 63.9% in patients with 
eGFR < 15 mL/min [6]. 
The adoption of a Western lifestyle by natives 
of other countries and cultures and a change in the 
socioeconomic background through immigration to 
Western countries and movement from rural to ur-
ban communities have influenced sUA levels [7, 8]. 
The pathophysiological effect  
of hyperuricemia on cardiovascular  
disease: What matters more?  
Overproduction or underexcretion?
First and foremost, an increased sUA level is 
the result of a purine/fructose-rich diet, genetic 
or environmental factors, metabolic disorders, as 
well as either: (1) its endogenous overproduction 
(due to, e.g., purine-rich diet, an error of purine 
metabolism affected by phoribosyl-pyrophosphate 
synthetase or purine salvage pathway influenced 
by hypoxanthine-xanthine phosphoribosyl trans-
ferase; cell breakdown or excessive purine turno-
ver: lymphoproliferative diseases, myeloprolifera-
tive disease, polycythemia vera, Paget disease [9], 
psoriasis, tumor lysis, hemolysis, rhabdomyolysis, 
and exercise; [10] or — in most cases — by 
(2) insufficient excretion (caused by acute or 
chronic kidney disease [CKD], acidosis: lactic 
acidosis, ketoacidosis; hypovolemia, medication/ 
/toxin: diuretic, niacin, pyrazinamide, ethambutol, 
cyclosporin, beryllium, salicylates, lead, alcohol; 
sarcoidosis, hyperparathyroidism, hypothyroidism, 
Bartter syndrome, and Down syndrome [11–13]. 
It should be emphasized that due to the limi-
tations of the current knowledge on what is more 
important for unfavorable cardiovascular effect of 
HU — overproduction of UA (increased activity 
of xanthine oxidase with reactive oxygen species 
formation) or limited excretion (effects of UA per 
se), the topic has become one of the hottest in the 
field of cardiovascular research and hyperuricemia. 
However, the mechanism of impaired oxidative 
mechanism which was widely described in a pre-
vious version of this document seems to be more 
consistent. 
Genetics: Possibilities for individualized 
diagnoses and care strategies? 
There is growing evidence that genetics and 
environmental factors play a key role in HU’s 
development [14]. Considering HU’s pathophysi-
ological aspects, it can be divided into overpro-
duction (liver) and underexcretion types (gut, 
kidney). Indeed, genome-wide association studies 
identified the genetic basis of HU as dominated by 
loci containing urate transporters and interacting 
proteins involved in the excretion of urate; among 
them SLC2A9 (GLUT9), ABCG2, SLC22A11, 
SLC17A1–SLC17A4, and PDZK1; and proteins 
associated with metabolic pathways (e.g., GCKR, 
A1CF, IGF1R) [15]. Among these, GLUT9 and 
ABCG2 were recognized as the most significant 
[16]. Indeed, SLC2A9 (GLUT9) has a key role in 
urate transport and reabsorption. GLUT9-encoded 
protein is useful in urate excretion into urine and 
the reabsorption of urate into the blood. Differ-
ences among variants of GLUT9 also influence 
the excretion of UA in urine and its reabsorption 
to blood [17]. Systematic analysis of GLUT9’s 
variants confirms its key role in the treatment of 
HU. Moreover, the ABCG2 gene (BCRP) is en-
gaged in intestinal excretion and UA transport in 
proximal tubule epithelial cells [18]. Mutations in 
ABCG2 impede proper sUA regulation and lead to 
HU. Of note, in hemochromatosis patients, iron/ 
/heme overload enhances the activity of xanthine 
oxidase and — through p53 — causes the reduction 
of ABCG2 expression. This leads to a reduction 
in UA intestinal excretion and subsequent accu-
mulation in tissue and serum, causing hereditary 
hemochromatosis-associated arthritis [19].
Among many others, one should acknowl-
edge organic anion transporters 10 (OAT10, 
SLC22A13), acting as a key part of urate transport 
from urine to the blood; lactate dehydrogenase D 
(LDHD), decreasing excretion of UA [20]; 
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hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT) whose deficiency caused by an HPRT1 
mutation leads to elevated UA levels in the blood, 
which are associated with Kelley-Seegmiller syn-
drome, Lesch-Nyhan syndrome, and HU [21]; 
mitochondrial seryl-tRNA synthetase precursor, 
a member of the class II tRNA synthetase family, 
which is involved in the ligation of serine to tRNA 
(Ser) and is involved in selenocysteinyl-tRNA 
(sec) biosynthesis in mitochondria [22]; xanthine 
dehydrogenase (XDH), influencing the oxidation 
of hypoxanthine to xanthine and the oxidation of 
xanthine to UA [23], therefore reducing the levels 
of xanthine oxidoreductase. Drabkin et al. [20] 
confirmed that a mutation could cause HU in LDHD 
within the putative catalytic site of the encoded 
d-lactate dehydrogenase, which results in increased 
blood levels of d-lactate — typically present in 
blood in miniscule amounts. As a consequence, 
excessive renal secretion of d-lactate in exchange 
for UA reabsorption culminates in HU. In line with 
the human phenotype, injection of d-lactate into 
naive mice resulted in HU [20]. 
These advances lead to a clear-cut approach 
to individualized patient care; genetic data can be 
informative about the prognosis in patients suffer-
ing from HU and help clinicians select dosage of 
urate-lowering therapy (ULT) and offer the correct 
advice on lifestyle changes.
Recent studies linking hyperuricemia  
to cardiovascular disease 
Hyperuricemia and ischemic heart disease
We look forward to the results of the ALL- 
-HEART study, which is a multicenter, controlled, 
prospective, randomized trial, examining the ef-
fects of allopurinol (up to 600 mg daily) vs. no 
treatment on cardiovascular outcome (non-fatal 
myocardial infarction, non-fatal stroke or cardio-
vascular death) in patients with coronary artery 
disease. The secondary goals are to determine the 
cost-effectiveness of adding allopurinol to usual 
therapy, determine whether allopurinol improves 
the quality of life, and to determine the safety and 
tolerability of giving allopurinol to patients with 
ischemic heart disease (without a history of gout). 
The main inclusion criteria were patients of 60 
years of age and over and ischemic heart disease. 
The main exclusion criteria were history of gout, 
eGFR < 30 mL/min, and moderate-to-severe heart 
failure and significant hepatic disease [24].
Hyperuricemia and hypertension
An ample body of evidence widely acknowl-
edges that the association between an increase 
in relative risk of hypertension and high levels of 
sUA remains independent of traditional risk factors 
[25–33]. A substantial meta-analysis of 18 studies 
confirmed an increase of 13% in the incidence of 
new-onset hypertension for every 1% increase in 
sUA levels [25]. The PAMELA (Pressioni Arte-
riose Monitorate e Loro Associazioni) study con-
firmed that a rise in sUA by 1 mg/dL was associated 
with a significant increase in the risk of developing 
the new-onset home and ambulatory hypertension 
(odds ratio [OR] 1.34, 95% CI 1.06–1.7, p = 0.015; 
OR 1.29, 95% CI 1.05–1.57, p = 0.014; respec-
tively) [26]. Finally, the Saku study confirmed that 
HU predicted the risk of developing hypertension 
was independent of alcohol drinking status [34].
Hyperuricemia and stroke
Serum uric acid plays a key and influential 
role in the physiopathology of stroke [35]. Kim 
et al. [36] reported that HU was associated with 
a significantly higher risk of both stroke incidence 
(relative risk [RR] 1.41) and mortality (RR 1.36) in 
their meta-analyses of unadjusted study estimates. 
Accordingly, Zhong et al. [37] in their meta-analysis 
confirmed similar results; elevated sUA levels 
were significantly associated with an increased 
risk of stroke in both men (RR 1.10 per 1 mg/dL 
increase in sUA) and women (RR 1.11 [1.09–1.13]). 
In the newest study to date; CIRCS investigators 
presented that elevated sUA level is an independ-
ent predictor of total stroke in women but not in 
men. The positive association present in women 
was mostly attributable to ischemic stroke and was 
more pronounced among nonusers of antihyperten-
sive medication [38].
Hyperuricemia and metabolic syndrome
As mentioned above, several studies demon-
strated that sUA level is associated with metabolic 
syndrome, high body mass index (BMI), waist 
circumference, high fasting blood glucose lev-
els, and dyslipidemia [39]. Shirasawa et al. [40] 
analyzed data derived from 96,863 participants 
and confirmed that the adjusted OR for HU was 
considerably increased in obesity (with central 
obesity) compared with normal weight, regardless 
of sex (men: OR 2.12, 95% CI 2.03–2.21; women: 
OR 3.54, 95% CI 3.21–3.90) and was statistically 
increased in normal weight with central obesity 
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compared to normal weight (men: OR 1.44, 95% 
CI 1.36–1.52; women: OR 1.41, 95% CI 1.27–1.57). 
They concluded that middle-aged Japanese adults 
with normal weight but having central obesity 
should be screened using a combination of BMI and 
waist to height ratio and be educated about how to 
prevent HU [40]. 
Hyperuricemia and atrial fibrillation
Currently, evidence on serum urate with the 
risk of atrial fibrillation (AF) is mainly from cross‐
sectional studies, based on prevalent AF cases, 
and were limited by only a 1-time measurement 
of serum urate. However, in a large prospective 
cohort study with 123,238 participants conducted 
from 2006 to 2012, both an increased cumulative 
average and elevations in serum urate over time 
were associated with increased risk of incident AF 
(adjusted hazard ratio [HR] 1.91, 95% CI 1.32–2.76, 
p = 0.001 for trend). The combination of high sUA 
and high-sensitivity C-reactive protein levels was 
associated with a significantly increased risk of 
incident AF (adjusted HR 2.63, 95% CI 1.63–4.23). 
Li et al. [41] provided evidence of an association 
between a relatively common treatable metabolic 
alteration (higher serum urate) and a common 
cardiac rhythm disorder (AF) with substantial 
morbidity and mortality. Moreover, Hong et al. [42] 
confirmed that the association between sUA and 
AF was significant (p = 0.001) after adjusting for 
potential confounding factors. 
Hyperuricemia and liver diseases
The relationship between HU and liver disease 
has not been clearly described. Undoubtedly, the 
increased level of sUA is the result of a diet rich 
in purine and fructose, genetic and environmental 
factors, metabolic disorders, as well as endogenous 
overproduction or — in most cases — impaired ex-
cretion of UA [43–46]. Uric acid synthesis is mainly 
influenced by phosphoribosyl pyrophosphate syn-
thetase and the purine pathway [46]. Some publica-
tions indicate the association of increased levels of 
sUA with non-alcoholic fatty liver disease, which 
is a part of metabolic syndrome, and chronic hepa-
titis. In experimental studies, the UA-stimulated 
expression of aldose reductase in both cultured 
hepatocytes (HepG2 cells) and hyperuricemic rat 
livers were associated with endogenous fructose 
production triglyceride accumulation through 
UA-induced oxidative stress and stimulation of 
the nuclear transcription factor activated T5 cells 
(NFAT5). Uric acid also potentiated the effects of 
elevated glucose levels to stimulate the accumu-
lation of triglycerides in the liver. Hyperuricemic 
rats exhibited elevated hepatic aldose reductase 
expression, endogenous fructose accumulation, 
and fat accumulation was significantly reduced by 
allopurinol co-administration. Thus, HU is corre-
lated with the occurrence of hypertriglyceridemia 
and non-alcoholic fatty liver disease, which sec-
ondarily induces the development of non-alcoholic 
steatohepatitis [47, 48].
Jang et al. [49] investigated UA levels and their 
relationship to disease progression in 373 patients 
with biopsy-confirmed chronic hepatitis C (CHC) 
enrolled in interferon-based antiviral therapy. In 
this study HU was defined as UA levels > 7 mg/dL 
in men and > 6.0 mg/dL in women. Hyperurice-
mia was found in 15.8% of CHC patients, but UA 
levels did not differ between CHC patients and the 
control group of healthy subjects matched for sex 
and age (5.54 ± 1.20 mg/dL vs. 5.45 ± 1.45 mg/dL, 
p = 0.3). Logistic regression analysis showed that 
factors related to HU in men included BMI (OR/CI 
1.12/1.05–1.30, p = 0.006) and advanced fibrosis 
(F3–4) (OR/CI 0.27/0.09–0.83, p = 0.02), while 
factors associated with HU in women included 
eGFR (OR/CI 0.97/0.95–0.99, p = 0.02) and diabe-
tes (OR/CI 3.03/1.11–8.25, p = 0.03). There was 
a significant downward trend in sUA levels with 
the progression of fibrosis in men (6.21 ± 1.03 mg/ 
/dL, 5.82 ± 1.16 mg/dL, and 5.44 ± 1.28 mg/dL in 
stages F0–2, F3 and F4, respectively, trend p = 0.01), 
indicating that HU was inversely related to the se-
verity of liver disease in men with CHC [49]. Petta 
et al. [50] do not share this opinion; in a study of 
496 patients with biopsy-confirmed CHC treated 
with pegylated interferon and ribavirin, there was 
no independent association between UA levels and 
necroinflammatory activity, fibrosis, nor sustained 
virologic response. However, the association of 
HU with the severity of steatosis was confirmed 
(OR 3.176, 95% CI 1.828–5.517, p <0.001), which 
could potentially be a therapeutic target in the 
treatment of CHC [50]. Moreover, Jang et al. [51], 
in a group of 213 patients, where HU was defined 
as UA levels > 7.0 mg/dL in men and > 6.0 mg/dL 
in women, showed that sUA levels decreased 
significantly after eradication of hepatitis C virus 
by the use of direct antiviral drugs. Improvement 
was only observed in patients with fibrosis-4 ratio 
(FIB-4) < 6.5 (37.1% vs. 25.7%, p = 0.001). The 
multivariate analysis showed that factors associ-
ated with significantly reduced sUA levels were 
FIB-4 < 6.5 (OR/95% CI 3.22/1.04–9.95, p = 0.04) 
and eGFR < 60 mL/min/1.73 m2 (OR/95% CI 
4.34/1.94–9.73, p < 0.001 [51]. 
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Hyperuricemia and COPD
Identification of prognostic biomarkers for 
chronic obstructive pulmonary disease (COPD) 
may help improve therapy for patients at high risk. 
In univariate analysis, HU was associated with 
a higher risk of mortality in patients with COPD 
(HR 2.29, 95% CI 1.07–4.88, p = 0.032). Further 
analysis confirmed that HU was independently 
associated with a higher risk of mortality in pa-
tients with COPD (HR 2.68, 95% CI 1.18–6.09, 
p = 0.019) [52]. Moreover, it was recently pub-
lished that sUA could activate the nucleotide-bind-
ing oligomerization domain-like receptor family 
pyrin domain-containing 3 (NLRP3) inflammasome, 
leading to interleukin (IL)-1b secretion. In COPD 
patients, UA and uric ratio with creatinine (UCR) 
were positively associated with white blood cells, 
C-reactive protein, and IL-1b. COPD smokers 
had lower UA and UCR values. Standard COPD 
therapy did not affect UA or UCR, while patients 
with cardiovascular diseases (CVD) had higher UA, 
but not UCR, levels. Multiparameter models of UA 
and UCR that included IL-1b were able to correctly 
classify 86% and 90% of cases, respectively [53].
Current uric acid thresholds predicting 
cardiovascular events: Including  
improved cardiovascular risk estimation
As described in a previous document [1], sUA 
is considered an independent factor in the devel-
opment of a wide variety of vascular disorders: 
hypertension [54], metabolic syndrome [55, 56], 
coronary artery disease [57], diabetes [58], cer-
ebrovascular disease [59, 60], CKD [61], as well 
as other CVD [62, 63] and — conversely — these 
comorbidities increase the incidence of HU [64]. 
It is worth paying attention to other conditions, 
both those from the genre of metabolic syndrome 
(e.g., non-alcoholic fatty liver, non-alcoholic stea-
tohepatitis) and those whose presence may affect 
the clinical course of disorders in the cardiovas-
cular system (e.g., COPD [65] or incident asthma 
in men [66]).
What we know so far, is that some studies have 
found a robust association between sUA level and 
CVD not only in patients with clearly diagnosed 
HU but also in those with values considered normal 
to high > 5.2–5.5 mg/dL [67–69]. Moreover, this 
relationship concerned both subclinical and clinical 
manifestations of diseases [64], and remained high-
ly significant even after renal function adjustment.
Of note, the Working Group on sUA and car-
diovascular risk within the Italian Society of Hy-
pertension designed the URRAH (Uric Acid Right 
for Heart Health) study, whose aim was to assess 
— in a group of 22,714 subjects — the level of UA 
above which the independent risk of CVD may 
increase in a significant manner in the general 
population [70]. Virdis et al. [71] confirmed that 
the threshold UA levels were 4.7 mg/dL (95% CI 
1.21–1.93 mg/dL) for increasing all-cause mortality, 
5.6 mg/dL (95% CI 4.99–6.21 mg/dL) for increas-
ing cardiovascular mortality, and were significantly 
lower than levels referenced in clinical diagnostic 
criteria [71]. Considering the sex of the patients, 
the threshold for sUA for all-cause mortality was 
5.4 mg/dL (95% CI 4.80–6.57) in men and 4.7 mg/dL 
(95% CI 4.40–5.10) in women. Most importantly for 
clinical practice is that the novel sUA thresholds 
allow for a significant net reclassification of — and 
improvement in — the Heart Score risk chart’s 
present values for all-cause and cardiovascular 
mortality, 0.26 and 0.27, respectively. 
In summation, this large-sample study led to 
a significant improvement in risk classification of 
the well-validated and guideline-recommended 
scale, the Heart Score. Further analysis for factors 
not included in the Heart Score such as hematocrit, 
diuretics, alcohol consumption, BMI, and eGFR 
did not significantly affect results [71]. The results 
reported by Virdis et al. [71] are largely superim-
posable over those obtained in several different 
populations of subjects enrolled in observational 
studies and show an increase in the relative risk 
of major cardiovascular events in the presence of 
sUA levels ranging between 4.5 and 5.5 mg/dL 
[72–75]. Previously reported investigations in 
smaller groups gave partially corroborative results 
specifically in the following contexts: in comparison 
to the Framingham Risk Score [72], in later life only 
[73], in patients undergoing percutaneous coronary 
interventions due to acute coronary syndrome 
[74], and in hypertensive patients; conflicting re-
sults were yielded in NHANES III [75]. The lower 
threshold level reported for CVD compared with 
gout can be explained by the causative role of the 
oxidative stress associated with the production of 
sUA by xanthine-oxidase that occurs with lower 
concentrations of serum urate and is largely inde-
pendent of the inflammatory role of UA deposition.
A large body of evidence confirms the contri-
bution of HU to the worsening of cardiovascular, 
diabetic, lipid, and renal diseases [76–78]; thereby 
supporting the conclusion that increased sUA 
levels correlate with elevated cardiovascular risk 
[79, 80] and further stressing the importance of 
a redefinition of threshold levels referred to during 
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identification of patients at risk of CVD in the pres-
ence of hyperuricemia. 
URRAH researchers identified the prognostic 
cut-off values of sUA in predicting fatal and morbid 
heart failure; sUA more than 5.34 mg/dL (CI 4.37– 
–5.6, sensitivity 52.32, specificity 63.96, p < 0.0001) 
was the univariate prognostic cut-off value for all 
heart failure, whereas sUA more than 4.89 mg/dL 
(CI 4.78–5.78, sensitivity 68.29, specificity 49.11, 
p < 0.0001) was the prognostic cut-off value for 
fatal heart failure [81]. Moreover, Huang et al. [82] 
analyzed ten studies involving 12,854 acute heart 
failure patients and confirmed that acute heart 
failure patients with the highest sUA levels had an 
increased risk of all-cause mortality (risk ratio [RR] 
1.43, 95% CI 1.31–1.56) and a combined endpoint of 
death or readmission (RR 1.68, 95% CI 1.33–2.13), 
after adjusting for potential variables. Therefore, 
elevation in sUA levels significantly increased risks 
of all-cause mortality and combined endpoint of 
death or readmission by 11% and 12%, respectively, 
for every 1 mg/mL, they were elevated [82]. Also, 
URRAH researchers adjusted for such confound-
ers as age, arterial hypertension, diabetes, CKD, 
smoking habits, ethanol intake, BMI, hematocrit, 
low-density lipoprotein cholesterol, and use of 
diuretics in multivariate Cox regression analyses 
and identified an independent association between 
sUA and fatal myocardial infarction across the 
whole database (HR 1.381, 95% CI 1.096–1.758, 
p = 0.006) and in women, specifically (HR 1.514, 
95% CI 1.105–2.075, p < 0.01), but not in men [83].
Hyperuricemia and cardiovascular 
events: A high serum uric acid level and 
its influence on cardiovascular outcome 
As we mentioned earlier, several studies 
have confirmed the relationship between sUA 
and CVD mortality [26, 84]. However, Rahimi-
-Sakak et al. [85] performed a meta-analysis of 44 
prospective cohort studies with dose-response 
analysis published between 2000 and 2018 to de-
termine the relationship between sUA and CVD 
mortality. Pooled results confirmed a significant 
positive association between sUA levels and risk 
of CVD mortality (HR 1.45, 95% CI 1.33–1.58, 
I2 = 79%). Sub-group analysis yielded that this 
association was stronger in women compared to 
men. Also, there was a significant non-linear asso-
ciation between sUA levels and CVD mortality risk 
(r = 0.0709, p = 0.001) [85]. In a cross-sectional 
study, Lee et al. [86] investigated the relationship 
of sUA with CVD risk in the Korean adult general 
population (8781 participants from first and second 
years of the Seventh Korea National Health and 
Nutrition Examination Survey 2016–2017). There 
was a significant association of sUA with 10-year 
CVD risk scores after adjusting for physical activ-
ity, BMI, serum creatinine, and alcohol consump-
tion in both sexes (p < 0.001); at sUA levels of 
6.9 mg/dL, the CVD risk was lowest [86].
Hyperuricemia treatment and  
cardiovascular outcomes: Allopurinol  
remains first-line urate-lowering therapy
In a systematic review of 24 guidance docu-
ments, 19 of them provided target levels for long-
-term sUA control, most of which recommended 
6.0 mg/dL (or 360 μmol/L), except the South Af-
rican guidelines, which recommended 5.0 mg/dL 
(300 μmol/L) [87]. Also, the Polish Society of 
Hypertension Guidelines 2019 recommend 
5.0 mg/dL level for long-term sUA control [88]. 
Still, the definition of HU varies greatly across 
clinical trials, making epidemiological reports 
somewhat inconsistent and difficult to compare.
Xanthine-oxidase inhibitors (XOI), especially 
allopurinol, are still recommended by almost all 
guidelines as a first-line ULT. The results on 
febuxostat have recently been implemented after 
publication of the FAST trial (long-term cardiovas-
cular safety of febuxostat compared with allopurinol 
in patients with gout: a multicenter, prospective, 
randomized, open-label, non-inferiority trial) [89, 
90] that reported divergent results from those 
described by the CARES (Cardiovascular Safety of 
Febuxostat and Allopurinol in Patients with Gout 
and Cardiovascular Morbidities) study [91].
Febuxostat: Further clinical trials needed?
Febuxostat, a nonpurine XOI, is recommended 
in patients refractory or intolerant to allopurinol 
and requires no dose limitation in CKD stages 
1–3. Febuxostat induces potent inhibition of XO 
and greater hypouricemic activity than the com-
monly used allopurinol doses [92]. However, pre-
liminary results from a safety trial with febuxostat 
versus allopurinol, mainly based on a large-scale, 
randomized study design has suggested a mod-
estly higher rate of cardiovascular events with 
febuxostat [93]. Based on the preceding study’s 
findings, treatment with febuxostat in patients 
at high cardiovascular risk has not been recom-
mended. Another safety oriented randomized 
controlled trial reporting results of a 32-month 
follow-up (n = 6190), demonstrated the compa-
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rable effects of febuxostat and allopurinol on the 
primary cardiovascular end-point with a higher 
rate in the secondary objectives of all-cause and 
cardiovascular mortality in the febuxostat group 
than in the allopurinol group (HR for death from 
any cause 1.22, 95% CI 1.01–1.47; HR for cardio-
vascular death 1.34, 95% CI 1.03–1.73) [91]. In the 
meantime, a meta-analysis of 35 studies did not 
show a significant difference between febuxostat 
and allopurinol in cardiovascular events (RR 1.69, 
95% CI 0.54–5.34, p = 0.37) [94]. Moreover, in 
the FREED study of over 1000 elderly patients 
with HU, 25% relative risk reduction in composite 
with death to any cause, cerebrovascular disease, 
non-fatal coronary artery disease, heart failure re-
quiring hospitalization, an arteriosclerotic disease 
requiring treatment, renal impairment, and AF was 
observed in the febuxostat group compared to the 
non-febuxostat group. There was no difference in 
cardiovascular clinical outcomes examined sepa-
rately with febuxostat versus control treatment.
In contrast, the European Medicines Agency 
(EMA)-required Febuxostat versus Allopurinol 
Streamlined Trial (FAST), published in the Lancet, 
does not support the finding of an increased car-
diovascular risk of febuxostat, despite using higher 
(EMA-approved) dosages compared to the CARES 
trial [90]. In 6128 patients (with previous CVD), for 
the incidence of the primary endpoint (a composite 
of hospitalization for non-fatal myocardial infarction 
or biomarker-positive acute coronary syndrome, 
non-fatal stroke, or cardiovascular death), on-treat-
ment, febuxostat (172 patients [1.72 events per 
100 patient-years]) was non-inferior to allopurinol 
(241 patients [2.05 events per 100 patient-years]; 
adjusted HR 0.85 [95% CI 0.70–1.03], p < 0.0001) 
[90]. In editorial comments, Bardin and Richette 
[89] underlined that patients in the CARES study 
had more severe gout than those in the FAST study 
and that all patients in CARES had a history of CVD 
in contrast to 2046 (33.4%) of 6128 in FAST. No 
excess of deaths was observed in this subgroup of 
patients in FAST. Still, their group size might be in-
sufficient to fully assess febuxostat risk in patients 
with severe CVD [89]. Thus, further clinical trials 
are needed to clarify this issue and provide clear 
evidence for the withdrawal of the Food and Drug 
Administration alert in this issue. 
Uric acid and COVID-19
There are not many studies on the relation-
ship between sUA and coronavirus disease 2019 
(COVID-19). However, of note that favipiravir, 
a purine nucleic acid analog and antiviral agent 
studied in Japan to treat COVID-19, has frequent 
side effects [95]. Favipiravir’s action causes it as 
a moderate inhibitor of organic anion transporters 
1 and 3 (OAT1 and OAT3), which are involved 
in UA excretion in the kidney, as well as by its 
influence on UA reuptake via urate transporter 1 
(URAT1) in the proximal renal tubules. Elevated 
UA levels were found to return to normal after 
discontinuation of favipiravir, and favipiravir is not 
recommended for long periods to treat viral infec-
tion [96, 97]. Moreover, in a Japanese, prospective, 
randomized, open-label trial of early versus late 
favipiravir treatment in hospitalized patients with 
COVID-19, 84.1% developed transient HU [98].
Management strategies: Updated  
five-step recommendations for the  
treatment of patients with increased  
serum uric acid levels (Fig. 1)
STEP 1: Assess serum uric acid level
The measurement of sUA concentration is 
recommended as a part of screening in cardiac/ 
/hypertensive patients by experts of both the 
European Society of Cardiology and the European 
Society of Hypertension [99]. 
Our recommendation remains unchanged: the 
optimal target of sUA levels should be 6 mg/dL 
(360 μmol/L). Serum uric acid levels should be 
monitored regularly and maintained at < 6 mg/dL. 
Still, despite the lack of randomized controlled tri-
als, one should consider an sUA target of < 5 mg/dL 
in patients with high cardiovascular risk comprised 
of at least two of the following: hypertension, dia-
betes, dyslipidemia, organ target organ damage or 
previous cardiovascular events.
STEP 2: Check comorbidities and active 
treatments and stop the administration  
of drugs that influence serum uric acid
Appropriate strategies should be defined and 
implemented in patients with HU, regarding more 
aggressive control of concomitant risk factors and 
the use of drugs indirectly affecting UA levels. Ef-
ficient management of concomitant diseases that 
influence sUA levels, such as hypertension, type 2 
diabetes, metabolic syndrome, CKD, and CVD [56, 
61–64] should be the procedure of choice. In clinical 
scenarios, feasible changes should be considered if 
the potential benefits exceed the potential harms, 
particularly:
 — Diuretics, among them hydrochlorothiazide 
— switching from hydrochlorothiazide to al-
ternative antihypertensive agents, if possible;
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 — Angiotensin II receptor blockers (ARBs) — 
although losartan is the only antihypertensive 
drug that lowers sUA level [100], switching from 
other ARBs to losartan is NOT recommended;
 — Low-dose acetylsalicylic acid (ASA) — cessa-
tion of low-dose ASA in primary cardiovascular 
prevention patients or switching to alterna-
tives, if possible; cessation of low-dose ASA in 
secondary cardiovascular prevention patients 
is NOT recommended;
 — Cholesterol-lowering agents — switching from 
cholesterol-lowering drugs to fenofibrate is 
NOT recommended.
Building multidisciplinary teams for optimal 
diagnostics and management strategies, with an 
appropriate estimation of HU’s significance, is 
necessary. It is essential to improve adherence 
to clinical practice guidelines, raise awareness of 
HU and associated comorbidities, and prompt their 
more diligent and specific monitoring.
STEP 3: Recommended life-style changes
Among the most significant lifestyle changes 
are:
 — Limiting intake of purines, including red meat 
and seafood;
 — Limiting intake of high-fructose corn syrup. 
Based on the Third National Health and Nutri-
tion Examination Survey, sUA levels increase 
with increasing sugar-sweetened soft drink 
intake. After adjusting for covariates, sUA 
levels associated with sugar-sweetened soft 
drink consumption categories (< 0.5, 0.5–0.9, 
1–3.9, and ≥ 4 servings/day) were greater than 
those associated with no intake (by 0.08, 0.15, 
0.33, and 0.42 mg/dL, respectively) (95% CI 
0.11–0.73, p < 0.001 for trend) [101];
 — Limiting alcohol. Limiting or abstaining 
from alcohol leads to decreased UA levels by 
1.6 mg/dL compared to the control group [102];
 — Weight loss and regular physical activity for pa-
tients who are overweight or obese [103, 104];
 — Adding coffee, dairy products, cherries [100, 
105], and ascorbic acid [106].
STEP 4: Give xanthine oxidase inhibitors 
as first-line therapy, titrated to achieve  
serum uric acid target
As mentioned earlier, allopurinol, XOI, is rec-
ommended as a first-line ULT in agreement with 
most of the guidelines. According to the summary 
of product characteristics of allopurinol, the rec-
Figure 1. Management strategy for patients suffering from hiperuricemia; CV — cardiovascular; SUA — serum uric 
acid.
5-STEP LADDER OF HIPERURICEMIA TREATMENT
CONSIDER STARTING ALLOPURINOL 100–200 mg DAILY, THEN TITRATE TO 300–600 mg 
DAILY TO REACH TARGETS OF < 6 mg/dL OR < 5 mg/dL IN HIGH CV RISK 
AND IN SPECIAL CASES, CONSIDER MAXIMUM DOSE 900 mg DAILY
ACHIEVE TARGET OF TREATMENT. DO NOT DISCONTINUE TREATMENT  
CONTINUE AND MONITOR SUA LEVEL TWICE EACH YEAR
IN SPECIAL CASES, CONSIDER A COMBINATION THERAPIES**
EDUCATE PATIENTS ABOUT THE DISEASE, LIFESTYLE AND PHYSICAL ACTIVITY  
ENSURE ADHERENCE TO LONG-TERM TREATMENT
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CONSIDER AS HIGH LEVEL OF ≥ 6 mg/dL OR ≥ 5 mg/dL IN HIGH CV RISK*
  
*At least two of the following are presented: hypertension, diabetes, dyslipidemia, organ target organ damage or previous CV events
**If treatment target is not reached, consider a strategy of allopurinol + uricosuric/lesinurad  
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IF POSSIBLE, DISCONTINUE DRUGS WHICH INCREASE SUA LEVEL
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ommended initial allopurinol dosage is 100 to 200 
mg daily in mild conditions, 300 to 600 mg daily in 
moderate conditions, 700 to 900 mg daily in severe 
conditions. The dosage should be titrated up 
to achieve the desired sUA target level [107]. 
Importantly — due to its renal excretion — in 
patients with CKD, impaired renal function may 
lead to retention of the drug and/or its metabo-
lites (oxypurinol) with subsequent prolongation of 
plasma half-lives. For this reason, in severe CKD, 
it may be appropriate to use less than 100 mg per 
day or to use single doses of 100 mg at longer 
intervals than 1 day. In special situations and the 
presence of appropriate equipment, the dose should 
be adjusted to maintain plasma oxypurinol levels 
below 100 μmol/L (15.2 mg/L). If allopurinol is 
used in dialysis patients, it should be administered 
at a 300–400 mg dose immediately after dialysis, 
but without additional doses on other days [107]. 
STEP 5: Achieve targeted serum uric acid 
levels, do not stop treatment, continue 
monitoring serum uric acid levels twice  
per year; in special cases, consider  
combined therapy
Only 2 in 5 patients with HU reached the tar-
get of sUA with this therapy [108]. Suppose that 
the sUA target cannot be achieved. In this case, 
the dose should be escalated with supervision up 
to 900 mg of allopurinol, or the patient should be 
switched to benzbromarone or combined therapy of 
benzbromarone and allopurinol (STEP 5), except 
in patients with eGFR of < 30 mL/min [109]. How-
ever, escalations should be performed carefully to 
achieve optimal treatment goals, mainly due to 
allopurinol hypersensitivity syndrome and severe 
cutaneous allergic reactions, usually after 8 weeks 
of therapy [110–112]. Factors that are known to 
contribute to the development of this syndrome 
include initial doses that are too high, CKD, ac-
companying use of diuretics, and the presence of 
HLA-B*5801 [113, 114]. 
Although high-dose allopurinol (≥ 300 mg/dL) 
is associated with a reduced risk of all-cause 
mortality [7, 115], consideration of an optimal 
dose seems to be a major factor design of future 
research.
Lesinurad is an oral selective inhibitor of 
URAT1 and OAT4 renal transporters, which in-
crease renal UA excretion and lower sUA levels by 
inhibiting UA reabsorption. A dose of 200 mg daily 
is recommended in combination with XOIs in pa-
tients who do not achieve treatment targets. Add-
ing lesinurad can increase the efficiency of XOIs 
(compared to monotherapy) and help avoid maximal 
XOI dosages [116]. In a CLEAR study, lesinurad 
of 200 mg or 400 mg together with allopurinol 
significantly increased the proportion of patients 
who achieved the sUA target levels compared to 
allopurinol (54.2%, 59.2%, and 27.9%, respectively, 
p < 0.0001) [117]. The approval of lesinurad was 
based on data from three pivotal phase III studies 
(CLEAR 1, CLEAR 2, and CRYSTAL), which as-
sessed lesinurad 200 mg and 400 mg doses. The 
target sUA level was achieved by significantly more 
patients on lesinurad 200 mg plus allopurinol group 
(CLEAR 1 and CLEAR 2 trials) or lesinurad 200 mg 
plus febuxostat group (CRYSTAL study) compared 
to patients who received either XOI alone. The 
safety profile of lesinurad 200 mg plus an XOI was 
comparable to allopurinol or febuxostat alone. To 
summarize, lesinurad, in combination with allopu-
rinol, is a novel option for the treatment of HU in 
adults with gout who have not achieved their target 
sUA levels with allopurinol alone (STEP 5) [118, 
119]. Once the sUA target is achieved continuously, 
ULT’s dose should be maintained indefinitely with 
ongoing monitoring of sUA levels twice a year 
(STEP 5) [117, 120].
Many unresolved questions still remain: 
Areas in need of further study
First and foremost, UA’s treatment target may 
still need to be reconsidered, especially since data 
from the URRAH study identified new cardio-
vascular thresholds and improved algorithms for 
assessing total cardiovascular risk. Still, there is 
a clear need for further evidence to support the 
treatment of asymptomatic HU, although a large 
body of evidence does show the beneficial effect 
of ULT on cardiovascular results. 
Most relevant recommendations:  
The take home message for the  
clinical practitioners
In conclusion, we would like to summarize our 
opinions that should be helpful to clinicians treating 
patients suffering from hyperuricemia and at high 
cardiovascular risk: 
 — 1 in 5 patients suffers from HU. The preva-
lence of HU is continuously increasing;
 — All patients with HU should be effectively 
informed about environmental and pharmaco-
logical factors influencing HU, comorbidities, 
and cardiovascular risk factors; be advised 
about the immediately required lifestyle and 
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diet modifications and weight loss, if neces-
sary; and strict adherence to recommended 
treatments;
 — Both patients and physicians of all specialties 
(especially primary care physicians, cardio-
logists, and pulmonologists) should strive to 
obtain and maintain lifelong sUA levels lower 
than 6 mg/dL; for patients at high cardiovas-
cular risk, the target level should be 5 mg/dL;
 — As mentioned earlier, allopurinol — a XOI — is 
recommended as a first-line ULT. According 
to the summary of product characteristics of 
allopurinol, the recommended initial allopuri-
nol dosage is 100 mg to 200 mg daily in mild 
conditions, 300 mg to 600 mg daily in moder-
ate conditions, and 700 mg to 900 mg daily in 
severe conditions;
 — The dosage of XOIs should be titrated up to 
achieve the desired sUA target level and moni-
tored twice a year thereafter to establish the 
correct level of sUA;
 — If the sUA target levels are not reached, com-
bined therapy of allopurinol + lesinurad might 
be considered.
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